Intravenous nitroglycerin as an experimental model of vascular headache. Basic characteristics
- PMID: 2506503
- DOI: 10.1016/0304-3959(89)90067-5
Intravenous nitroglycerin as an experimental model of vascular headache. Basic characteristics
Abstract
To develop a reliable experimental model of vascular headache, we studied the dose-response relationship between headache and i.v. nitroglycerin (NTG) in 10 healthy subjects. NTG was infused intravenously over periods of 10 min separated by wash-out periods. Doses of 0.25, 0.50, 1.00 and 2.00 micrograms/kg/min were applied successively with one placebo infusion and wash-out period inserted randomly and double blindly. The subjects scored their headache intensity on a scale 0-10. After 1-8 weeks a retest was performed. Nine subjects developed headache already at 0.25 microgram/kg/min, whereas one had no headache at any dose. Headache severity did not increase with doses above 0.5 microgram/kg/min. This ceiling effect was reproducible. The headache was moderate, usually throbbing, bifrontal and not associated with other migrainous features. It reached maximum within 2.5-5.5 min (medians) at various doses and declined rapidly after NTG discontinuation. Wash-out periods of 10-20 min were sufficient. The reproducibility of headache intensity and character was satisfactory in the retest experiment. There were no unpleasant side effects and no visible flushing. Thus blindness was maintained. I.v. NTG is suitable as an experimental headache model. A constant infusion of 0.5 microgram/kg/min will be suitable for studies of arterial diameter, pulsations, blood flow, etc. Comparative studies of sensitivity should use the present infusion schedule but with the two highest doses substituted by 0.06 and 0.125 microgram/kg/min.
Similar articles
-
Lack of tolerance of headache and radial artery diameter during a 7 hour intravenous infusion of nitroglycerin.Eur J Clin Pharmacol. 1993;44(1):47-50. doi: 10.1007/BF00315279. Eur J Clin Pharmacol. 1993. PMID: 8436154 Clinical Trial.
-
Association of methemoglobinemia and intravenous nitroglycerin administration.Am J Cardiol. 1985 Jan 1;55(1):181-3. doi: 10.1016/0002-9149(85)90324-8. Am J Cardiol. 1985. PMID: 3917597
-
Safety of intravenous nitroglycerin after administration of sildenafil citrate to men with coronary artery disease: a double-blind, placebo-controlled, randomized, crossover trial.Crit Care Med. 2007 Aug;35(8):1863-8. doi: 10.1097/01.CCM.0000269371.70738.30. Crit Care Med. 2007. PMID: 17522570 Clinical Trial.
-
Clevidipine: a review of its use in the management of acute hypertension.Am J Cardiovasc Drugs. 2009;9(2):117-34. doi: 10.2165/00129784-200909020-00006. Am J Cardiovasc Drugs. 2009. PMID: 19331440 Review.
-
Nitroglycerin headache and nitroglycerin-induced primary headaches from 1846 and onwards: a historical overview and an update.Headache. 2009 Mar;49(3):445-56. doi: 10.1111/j.1526-4610.2009.01342.x. Headache. 2009. PMID: 19267787 Review.
Cited by
-
Peripheral nerve stimulation for the treatment of primary headache.Curr Pain Headache Rep. 2013 Mar;17(3):319. doi: 10.1007/s11916-012-0319-2. Curr Pain Headache Rep. 2013. PMID: 23338771 Review.
-
Gene Network Dysregulation in the Trigeminal Ganglia and Nucleus Accumbens of a Model of Chronic Migraine-Associated Hyperalgesia.Front Syst Neurosci. 2018 Dec 18;12:63. doi: 10.3389/fnsys.2018.00063. eCollection 2018. Front Syst Neurosci. 2018. PMID: 30618656 Free PMC article.
-
Long-Term Depression Induced by Optogenetically Driven Nociceptive Inputs to Trigeminal Nucleus Caudalis or Headache Triggers.J Neurosci. 2018 Aug 22;38(34):7529-7540. doi: 10.1523/JNEUROSCI.3032-17.2018. Epub 2018 Jul 27. J Neurosci. 2018. PMID: 30054391 Free PMC article.
-
The pharmacological effect of BGC20-1531, a novel prostanoid EP4 receptor antagonist, in the prostaglandin E2 human model of headache.J Headache Pain. 2011 Oct;12(5):551-9. doi: 10.1007/s10194-011-0358-9. Epub 2011 Jun 17. J Headache Pain. 2011. PMID: 21681585 Free PMC article. Clinical Trial.
-
Dynamic sodium imaging at ultra-high field reveals progression in a preclinical migraine model.Pain. 2018 Oct;159(10):2058-2065. doi: 10.1097/j.pain.0000000000001307. Pain. 2018. PMID: 29905652 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources